Akums Drugs & Pharmaceuticals Ltd.
National Stock Exchange of IndiaTotal Valuation
Akums Drugs & Pharmaceuticals Ltd. carries a market capitalization of 99.75B, placing it among publicly traded companies globally. Its enterprise value stands at 56.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 99.75B |
| Enterprise Value | 56.64B |
Share Statistics
Akums Drugs & Pharmaceuticals Ltd. currently has 153.10M shares outstanding.
| Shares Outstanding | 153.10M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Akums Drugs & Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 27.96. The price-to-sales ratio is 1.64, and the price-to-book ratio stands at 3.37.
| PE Ratio | 27.96 |
| PS Ratio | 1.64 |
| PB Ratio | 3.37 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Akums Drugs & Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 15.41 and an EV/FCF ratio of 98.38. The EV/Sales ratio of 1.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.41 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.30 |
| EV / EBITDA | 15.41 |
| EV / EBIT | 15.41 |
| EV / FCF | 98.38 |
Financial Position
Akums Drugs & Pharmaceuticals Ltd. maintains a current ratio of 3.25, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.76, indicating elevated leverage, while an interest coverage ratio of 4.28 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.25 |
| Quick Ratio | 1.54 |
| Debt / Equity | 5.76 |
| Debt / EBITDA | 0.52 |
| Interest Coverage | 4.28 |
Financial Efficiency
Akums Drugs & Pharmaceuticals Ltd. posts a return on equity of 12.84 and a return on invested capital of 7.49.
| Return on Equity (ROE) | 12.84 |
| Return on Assets (ROA) | 5.34 |
| Return on Invested Capital (ROIC) | 7.49 |
| Return on Capital Employed (ROCE) | 14.52 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.50 |
Taxes
Over the trailing twelve months, Akums Drugs & Pharmaceuticals Ltd. has paid 1.26B in income taxes, reflecting an effective tax rate of 32.90.
| Income Tax | 1.26B |
| Effective Tax Rate | 32.90 |
Stock Price Statistics
Akums Drugs & Pharmaceuticals Ltd.'s stock has gained approximately 14.3183% over the past 52 weeks. The 50-day moving average sits at 563.70, while the 200-day moving average is 485.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 14.3183% |
| 50-Day Moving Average | 563.70 |
| 200-Day Moving Average | 485.54 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Akums Drugs & Pharmaceuticals Ltd. generated 43.59B in revenue and converted that into 2.55B in net income, yielding earnings per share of 16.75. EBITDA reached 3.67B, while operating income came in at 3.67B.
| Revenue | 43.59B |
| Gross Profit | 18.45B |
| Operating Income | 3.67B |
| Pretax Income | 3.82B |
| Net Income | 2.55B |
| EBITDA | 3.67B |
| EBIT | 3.67B |
| Earnings Per Share (EPS) | 16.75 |
Balance Sheet
Akums Drugs & Pharmaceuticals Ltd. holds 16.81B in cash and equivalents against 1.92B in total debt, resulting in a net debt position of -2.79B. Total book value stands at 21.16B, with working capital of 24.65B providing operational flexibility.
| Cash & Cash Equivalents | 16.81B |
| Total Debt | 1.92B |
| Net Debt | -2.79B |
| Equity (Book Value) | 21.16B |
| Book Value Per Share | 138.21 |
| Working Capital | 24.65B |
Margins
Akums Drugs & Pharmaceuticals Ltd. operates with a gross margin of 42.34, reflecting its pricing power and cost economics. The operating margin of 8.43 and net profit margin of 5.85 provide insight into operational efficiency.
| Gross Margin | 42.34 |
| Operating Margin | 8.43 |
| Pretax Margin | 8.77 |
| Profit Margin | 5.85 |
| EBITDA Margin | 8.43 |
Scores
Akums Drugs & Pharmaceuticals Ltd. posts an Altman Z-Score of 4.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.13 |